NYSEMKT: VNRXVolitionrx Ltd Stock
$0.85+0.25 (+41.67%)
Updated Apr 23, 2024
VNRX Price
$0.85
Fair Value Price
N/A
Market Cap
$69.76M
52 Week Low
$0.55
52 Week High
$2.10
P/E
-1.7x
P/B
-8.94x
P/S
65.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$775.30k
Earnings
-$35.32M
Gross Margin
100%
Operating Margin
-4,526.94%
Profit Margin
-4,555.5%
Debt to Equity
-4.7
Operating Cash Flow
-$18M
Beta
0.99
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VNRX Overview
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The firm is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The firm has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The firm's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The firm is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The firm's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. The company has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VNRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VNRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VNRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VNRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VNRX due diligence checks available for Premium users.
Be the first to know about important VNRX news, forecast changes, insider trades & much more!
VNRX News
Valuation
VNRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.7x
Industry
38.97x
Market
41.92x
VNRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.94x
Industry
4.24x
VNRX's financial health
Profit margin
Revenue
$244.0k
Net Income
-$8.7M
Profit Margin
-3,565.3%
VNRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VNRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.0M
Liabilities
$36.7M
Debt to equity
-4.7
VNRX's short-term liabilities ($31.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VNRX's short-term assets ($21.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VNRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VNRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$6.4M
Investing
-$308.7k
Financing
$3.8M
VNRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VNRX vs Diagnostic & Research Stocks
Volitionrx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.